Shanghai Yizhong announced that the company recently received the “Drug Clinical Trial Approval Notice” issued by the State Drug Administration, and the clinical trial application for the self-developed innovative drug YXC-002 for the treatment of non-small cell lung cancer has been officially approved.

Zhitongcaijing · 3d ago
Shanghai Yizhong announced that the company recently received the “Drug Clinical Trial Approval Notice” issued by the State Drug Administration, and the clinical trial application for the self-developed innovative drug YXC-002 for the treatment of non-small cell lung cancer has been officially approved.